Novel Antigen Binding Domain Identification via Immune Cell Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing infectious diseases and cancer lack effective solutions for identifying and targeting novel antigen binding domains, which are crucial for developing therapeutic strategies.
Innovation Solution
The development of chimeric antigen receptors (CARs) with novel antigen binding domains obtained from immune subjects, combined with CAR chassis, to create libraries of CAR constructs that can target specific antigens associated with diseases, using nucleic acids from immune cells and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional methods are used to identify antigen binding domains, then the process is simple and straightforward, but the ability to find novel and effective antigen targets is limited
Solution Approach 1:
The patent performs preliminary action by isolating and characterizing antigen binding domains from immune cells before they are needed for therapeutic application. The method pre-identifies novel antigen binding domains from subjects with immune responses, creating a ready pool of validated targets that can be rapidly deployed when needed, thus improving adaptability without increasing operational complexity.
Solution Approach 2:
The patent applies self-service by utilizing the subject's own immune system to generate and present novel antigen binding domains. The immune cells from subjects who have naturally developed immune responses provide the antigen binding domains autonomously, eliminating the need for complex external screening and validation processes.
2Reliability
If CAR constructs are engineered with novel antigen binding domains from immune subjects, then therapeutic effectiveness against disease antigens is improved, but the complexity of constructing and validating CAR libraries increases
Solution Approach 1:
The patent applies segmentation by dividing the CAR construction process into separate, manageable components: (1) isolation of antigen binding domains from immune cells, (2) validation of antigen binding activity, and (3) integration into CAR chassis. This modular approach allows each segment to be optimized independently, improving therapeutic effectiveness while making the overall process more tractable.
Solution Approach 2:
The patent changes key parameters by using antigen binding domains from subjects with established immune responses, which naturally have optimized binding affinity and specificity. This parameter change (source of antigen binding domain) improves therapeutic effectiveness while the standardized validation protocols reduce the complexity of verification.
3Productivity
If the immune system's ability to recognize disease-specific antigens is enhanced through novel antigen binding domains, then the effectiveness of treating infectious diseases and cancer is improved, but the time and resources required for identification and validation increase
Solution Approach 1:
The patent performs preliminary identification and validation of antigen binding domains from immune cells before clinical application. By pre-characterizing these domains and verifying their antigen binding capabilities, the method creates a ready-to-use library that can be rapidly deployed for therapeutic purposes, thus improving treatment productivity without significantly increasing the time required for actual disease intervention.
Data Source
AI summary
The present invention relates generally to the field of making novel antigen binding domains against infectious diseases. The present invention also relates to novel CARs that utilize the novel antigen binding domains as an extracellular element. The present invention also relates to use of the novel antigen binding domains as therapeutic agents.